StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Five Prime Therapeutics (FPRX) Enters Collaboration with Bristol-Myers Squibb (BMY) Worth Up to $1.74B
October 15, 2015 6:06 AM
Bristol-Myers Squibb Company (NYSE: BMY) and Five Prime Therapeutics, Inc.(Nasdaq: FPRX) today announced that they have entered into an exclusive ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Momentum Movers
Trader Talk
Next Articles
Oppenheimer Raises Price Target Following Five Prime Therapeutics' (FPRX) Announced Licensing Agreement with BMY
October 19, 2015 6:42 AM
Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY
October 15, 2015 4:06 PM
Five Prime Therapeutics (FPRX) Sees Windfall on Anti-CSF1R Collaboration Agreement (BMY)
October 15, 2015 9:20 AM
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015 4:00 AM
